| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcohol Drinking | 42 | 2025 | 287 | 9.850 |
Why?
|
| Smoking Cessation | 28 | 2025 | 272 | 8.440 |
Why?
|
| Alcoholism | 23 | 2025 | 191 | 7.050 |
Why?
|
| Ethanol | 37 | 2025 | 270 | 6.830 |
Why?
|
| Smoking | 27 | 2025 | 653 | 6.290 |
Why?
|
| Electronic Nicotine Delivery Systems | 10 | 2025 | 84 | 5.250 |
Why?
|
| Naltrexone | 16 | 2019 | 139 | 4.420 |
Why?
|
| Cues | 11 | 2025 | 189 | 4.060 |
Why?
|
| Vaping | 6 | 2025 | 53 | 3.460 |
Why?
|
| Reward | 9 | 2025 | 209 | 3.040 |
Why?
|
| Narcotic Antagonists | 12 | 2019 | 170 | 2.970 |
Why?
|
| Alcoholic Intoxication | 7 | 2025 | 37 | 2.380 |
Why?
|
| Tobacco Products | 6 | 2025 | 80 | 2.280 |
Why?
|
| Smokers | 6 | 2025 | 55 | 2.140 |
Why?
|
| Adult | 89 | 2025 | 28725 | 2.020 |
Why?
|
| Young Adult | 50 | 2025 | 7025 | 1.820 |
Why?
|
| Tobacco Use Disorder | 7 | 2019 | 122 | 1.800 |
Why?
|
| Nicotine | 7 | 2025 | 210 | 1.750 |
Why?
|
| Alcoholic Beverages | 4 | 2021 | 14 | 1.750 |
Why?
|
| Hydrocortisone | 14 | 2025 | 300 | 1.680 |
Why?
|
| Male | 88 | 2025 | 45871 | 1.570 |
Why?
|
| Central Nervous System Depressants | 9 | 2021 | 45 | 1.550 |
Why?
|
| Craving | 5 | 2019 | 24 | 1.490 |
Why?
|
| Female | 86 | 2025 | 50045 | 1.450 |
Why?
|
| Motivation | 6 | 2021 | 310 | 1.400 |
Why?
|
| Double-Blind Method | 25 | 2019 | 1791 | 1.400 |
Why?
|
| Tobacco Smoking | 2 | 2021 | 31 | 1.250 |
Why?
|
| Humans | 107 | 2025 | 96112 | 1.250 |
Why?
|
| Affect | 9 | 2025 | 397 | 1.250 |
Why?
|
| Psychomotor Performance | 8 | 2018 | 505 | 1.210 |
Why?
|
| Mobile Applications | 2 | 2021 | 79 | 1.190 |
Why?
|
| Alcohol-Related Disorders | 3 | 2021 | 18 | 1.180 |
Why?
|
| Surveys and Questionnaires | 15 | 2025 | 2860 | 1.090 |
Why?
|
| Tobacco Use Cessation | 2 | 2017 | 9 | 1.040 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2018 | 26 | 0.970 |
Why?
|
| Behavior, Addictive | 5 | 2019 | 137 | 0.970 |
Why?
|
| Smoking Reduction | 1 | 2025 | 4 | 0.920 |
Why?
|
| Carcinogens | 1 | 2025 | 106 | 0.890 |
Why?
|
| Hypnotics and Sedatives | 3 | 2017 | 142 | 0.890 |
Why?
|
| Smartphone | 3 | 2025 | 54 | 0.880 |
Why?
|
| Cigarette Smoking | 1 | 2025 | 48 | 0.870 |
Why?
|
| Sexual and Gender Minorities | 2 | 2019 | 250 | 0.860 |
Why?
|
| Courage | 1 | 2023 | 8 | 0.790 |
Why?
|
| Behavior Therapy | 2 | 2021 | 95 | 0.790 |
Why?
|
| Psychometrics | 6 | 2018 | 340 | 0.780 |
Why?
|
| Depression | 2 | 2025 | 560 | 0.770 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2025 | 1973 | 0.720 |
Why?
|
| Binge Drinking | 3 | 2022 | 15 | 0.700 |
Why?
|
| Telemedicine | 1 | 2025 | 229 | 0.690 |
Why?
|
| Impulsive Behavior | 3 | 2019 | 290 | 0.690 |
Why?
|
| Self Efficacy | 2 | 2019 | 61 | 0.680 |
Why?
|
| Crisis Intervention | 1 | 2021 | 13 | 0.680 |
Why?
|
| Middle Aged | 34 | 2025 | 28371 | 0.680 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1176 | 0.670 |
Why?
|
| Patient Selection | 2 | 2017 | 709 | 0.650 |
Why?
|
| Biomarkers | 3 | 2025 | 1932 | 0.640 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2018 | 504 | 0.630 |
Why?
|
| Sex Factors | 9 | 2018 | 1133 | 0.630 |
Why?
|
| Self Report | 5 | 2020 | 328 | 0.620 |
Why?
|
| Saccades | 3 | 2013 | 75 | 0.620 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 3927 | 0.620 |
Why?
|
| Genotype | 3 | 2019 | 1882 | 0.610 |
Why?
|
| Smoking Prevention | 4 | 2022 | 46 | 0.590 |
Why?
|
| Receptors, Opioid | 1 | 2019 | 23 | 0.590 |
Why?
|
| Glycerol | 1 | 2019 | 37 | 0.590 |
Why?
|
| Vegetables | 1 | 2019 | 50 | 0.580 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2018 | 37 | 0.570 |
Why?
|
| Central Nervous System Stimulants | 2 | 2019 | 235 | 0.570 |
Why?
|
| Research Design | 2 | 2012 | 631 | 0.560 |
Why?
|
| Nicotinic Agonists | 3 | 2022 | 74 | 0.560 |
Why?
|
| Treatment Outcome | 13 | 2019 | 9176 | 0.550 |
Why?
|
| Tobacco Use | 1 | 2018 | 31 | 0.540 |
Why?
|
| Social Behavior | 4 | 2018 | 309 | 0.540 |
Why?
|
| Feasibility Studies | 5 | 2025 | 819 | 0.530 |
Why?
|
| Stimulation, Chemical | 1 | 2017 | 63 | 0.530 |
Why?
|
| Pilot Projects | 7 | 2022 | 938 | 0.530 |
Why?
|
| Substance Withdrawal Syndrome | 4 | 2012 | 53 | 0.520 |
Why?
|
| Professional Practice | 1 | 2017 | 45 | 0.510 |
Why?
|
| Pituitary-Adrenal System | 3 | 2012 | 64 | 0.510 |
Why?
|
| Homosexuality, Female | 1 | 2017 | 17 | 0.510 |
Why?
|
| Referral and Consultation | 2 | 2024 | 386 | 0.510 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 2012 | 81 | 0.510 |
Why?
|
| Bisexuality | 1 | 2017 | 36 | 0.510 |
Why?
|
| Sex Characteristics | 4 | 2012 | 339 | 0.500 |
Why?
|
| Research Subjects | 1 | 2017 | 73 | 0.500 |
Why?
|
| Health Personnel | 1 | 2019 | 241 | 0.500 |
Why?
|
| Transsexualism | 1 | 2017 | 37 | 0.490 |
Why?
|
| Health Promotion | 3 | 2014 | 176 | 0.490 |
Why?
|
| Psychotherapy, Brief | 1 | 2015 | 13 | 0.470 |
Why?
|
| Feedback, Psychological | 1 | 2015 | 20 | 0.460 |
Why?
|
| Weight Gain | 2 | 2012 | 129 | 0.450 |
Why?
|
| Luteal Phase | 1 | 2014 | 14 | 0.450 |
Why?
|
| Follicular Phase | 1 | 2014 | 11 | 0.440 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 829 | 0.440 |
Why?
|
| Drinking Behavior | 1 | 2014 | 13 | 0.440 |
Why?
|
| Breath Tests | 5 | 2025 | 58 | 0.440 |
Why?
|
| Prolactin | 1 | 2014 | 89 | 0.440 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2021 | 569 | 0.430 |
Why?
|
| Saliva | 7 | 2015 | 128 | 0.430 |
Why?
|
| Stress, Psychological | 5 | 2013 | 347 | 0.410 |
Why?
|
| Biosensing Techniques | 2 | 2025 | 81 | 0.410 |
Why?
|
| Psychotherapy, Group | 2 | 2013 | 37 | 0.410 |
Why?
|
| Community Health Services | 1 | 2014 | 81 | 0.400 |
Why?
|
| Homosexuality, Male | 1 | 2017 | 332 | 0.400 |
Why?
|
| Eye Movements | 2 | 2012 | 119 | 0.400 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 3 | 2016 | 286 | 0.400 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 53 | 0.380 |
Why?
|
| Biomedical Research | 1 | 2017 | 441 | 0.370 |
Why?
|
| Sexual Partners | 1 | 2013 | 106 | 0.370 |
Why?
|
| Medical Records | 1 | 2012 | 126 | 0.360 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 647 | 0.350 |
Why?
|
| Internet | 2 | 2019 | 340 | 0.350 |
Why?
|
| Adolescent | 13 | 2025 | 9895 | 0.350 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 935 | 0.340 |
Why?
|
| Mental Recall | 1 | 2012 | 173 | 0.340 |
Why?
|
| Eligibility Determination | 1 | 2011 | 38 | 0.330 |
Why?
|
| Cotinine | 2 | 2025 | 15 | 0.330 |
Why?
|
| Poverty | 2 | 2023 | 196 | 0.330 |
Why?
|
| Sexual Behavior | 1 | 2013 | 334 | 0.320 |
Why?
|
| Pursuit, Smooth | 2 | 2013 | 31 | 0.310 |
Why?
|
| Physicians | 1 | 2017 | 707 | 0.310 |
Why?
|
| Basal Ganglia | 1 | 2009 | 47 | 0.310 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2009 | 6 | 0.300 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2013 | 296 | 0.300 |
Why?
|
| Chicago | 5 | 2019 | 1506 | 0.300 |
Why?
|
| Amygdala | 3 | 2016 | 87 | 0.290 |
Why?
|
| Social Environment | 2 | 2007 | 195 | 0.290 |
Why?
|
| Administration, Cutaneous | 2 | 2022 | 61 | 0.290 |
Why?
|
| Substance-Related Disorders | 4 | 2020 | 451 | 0.280 |
Why?
|
| Analysis of Variance | 7 | 2016 | 909 | 0.270 |
Why?
|
| Time Factors | 6 | 2025 | 5585 | 0.270 |
Why?
|
| Preventive Health Services | 1 | 2008 | 39 | 0.270 |
Why?
|
| Anger | 3 | 2016 | 81 | 0.260 |
Why?
|
| Oxytocin | 2 | 2018 | 75 | 0.250 |
Why?
|
| Aged | 11 | 2025 | 20972 | 0.250 |
Why?
|
| Attitude to Health | 1 | 2008 | 226 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1471 | 0.240 |
Why?
|
| Residence Characteristics | 1 | 2008 | 213 | 0.240 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 1089 | 0.240 |
Why?
|
| Blood Alcohol Content | 2 | 2022 | 7 | 0.240 |
Why?
|
| Cultural Characteristics | 2 | 2019 | 19 | 0.240 |
Why?
|
| Nitrosamines | 1 | 2025 | 9 | 0.230 |
Why?
|
| Family Health | 2 | 2018 | 159 | 0.230 |
Why?
|
| Wearable Electronic Devices | 1 | 2025 | 36 | 0.220 |
Why?
|
| Substance Abuse Treatment Centers | 2 | 2004 | 25 | 0.220 |
Why?
|
| Cohort Studies | 3 | 2019 | 3110 | 0.210 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2024 | 18 | 0.210 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2024 | 24 | 0.210 |
Why?
|
| Patient Dropouts | 1 | 2004 | 31 | 0.210 |
Why?
|
| Risk Factors | 5 | 2022 | 5961 | 0.200 |
Why?
|
| Photic Stimulation | 4 | 2015 | 514 | 0.200 |
Why?
|
| Cancer Survivors | 1 | 2025 | 88 | 0.200 |
Why?
|
| Prospective Studies | 3 | 2019 | 4672 | 0.200 |
Why?
|
| United States | 5 | 2024 | 7768 | 0.200 |
Why?
|
| Life Change Events | 1 | 2003 | 50 | 0.190 |
Why?
|
| Prevalence | 4 | 2020 | 1349 | 0.190 |
Why?
|
| Counseling | 3 | 2015 | 174 | 0.190 |
Why?
|
| Melatonin | 1 | 2022 | 48 | 0.190 |
Why?
|
| Machine Learning | 1 | 2025 | 348 | 0.180 |
Why?
|
| Health Behavior | 2 | 2017 | 191 | 0.180 |
Why?
|
| Personality | 1 | 2003 | 140 | 0.180 |
Why?
|
| Radiology | 1 | 2024 | 206 | 0.170 |
Why?
|
| Risk Reduction Behavior | 2 | 2013 | 99 | 0.170 |
Why?
|
| Tablets | 1 | 2022 | 127 | 0.170 |
Why?
|
| Motivational Interviewing | 1 | 2021 | 22 | 0.170 |
Why?
|
| Program Evaluation | 3 | 2013 | 323 | 0.170 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 94 | 0.160 |
Why?
|
| Marijuana Smoking | 1 | 2020 | 28 | 0.160 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 2883 | 0.160 |
Why?
|
| Marketing | 1 | 2019 | 24 | 0.150 |
Why?
|
| Women | 1 | 2019 | 26 | 0.150 |
Why?
|
| Environment | 1 | 2021 | 231 | 0.150 |
Why?
|
| Exhalation | 1 | 2019 | 13 | 0.150 |
Why?
|
| Aerosols | 1 | 2019 | 48 | 0.150 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 1981 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 2494 | 0.150 |
Why?
|
| Heart Rate | 2 | 2018 | 519 | 0.140 |
Why?
|
| Phenotype | 2 | 2015 | 2579 | 0.140 |
Why?
|
| Heterozygote | 1 | 2018 | 382 | 0.130 |
Why?
|
| Mass Screening | 3 | 2024 | 710 | 0.130 |
Why?
|
| Adrenocorticotropic Hormone | 3 | 2009 | 132 | 0.130 |
Why?
|
| China | 2 | 2015 | 264 | 0.130 |
Why?
|
| Illinois | 1 | 2019 | 531 | 0.130 |
Why?
|
| Administration, Oral | 2 | 2012 | 688 | 0.130 |
Why?
|
| Culture | 1 | 2017 | 54 | 0.130 |
Why?
|
| Disease Progression | 1 | 2021 | 1564 | 0.120 |
Why?
|
| Retinal Rod Photoreceptor Cells | 1 | 2015 | 11 | 0.120 |
Why?
|
| Patient-Centered Care | 2 | 2020 | 228 | 0.110 |
Why?
|
| Retinal Cone Photoreceptor Cells | 1 | 2015 | 42 | 0.110 |
Why?
|
| Alcohol Abstinence | 1 | 2014 | 7 | 0.110 |
Why?
|
| Qualitative Research | 1 | 2017 | 361 | 0.110 |
Why?
|
| Mental Disorders | 1 | 2019 | 463 | 0.110 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 640 | 0.110 |
Why?
|
| Interviews as Topic | 2 | 2013 | 376 | 0.100 |
Why?
|
| Ecological Momentary Assessment | 2 | 2025 | 39 | 0.100 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2013 | 18 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2019 | 10287 | 0.100 |
Why?
|
| Color Vision Defects | 1 | 2012 | 22 | 0.100 |
Why?
|
| Cross-Over Studies | 2 | 2013 | 397 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 491 | 0.090 |
Why?
|
| Aggression | 1 | 2016 | 330 | 0.090 |
Why?
|
| Contrast Sensitivity | 1 | 2012 | 72 | 0.090 |
Why?
|
| Genetics, Behavioral | 1 | 2012 | 22 | 0.090 |
Why?
|
| Papillomaviridae | 1 | 2013 | 180 | 0.090 |
Why?
|
| Amphetamine | 1 | 2012 | 102 | 0.090 |
Why?
|
| Quinoxalines | 1 | 2012 | 51 | 0.090 |
Why?
|
| Visual Pathways | 1 | 2012 | 155 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2016 | 3652 | 0.090 |
Why?
|
| Benzazepines | 1 | 2012 | 65 | 0.090 |
Why?
|
| Emotions | 2 | 2016 | 377 | 0.090 |
Why?
|
| Community Health Centers | 1 | 2013 | 120 | 0.090 |
Why?
|
| Prefrontal Cortex | 1 | 2013 | 150 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 2463 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 2474 | 0.080 |
Why?
|
| Fear | 1 | 2010 | 88 | 0.080 |
Why?
|
| Patient Compliance | 2 | 2009 | 239 | 0.080 |
Why?
|
| Age Factors | 1 | 2014 | 1963 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 301 | 0.080 |
Why?
|
| Placebos | 1 | 2009 | 213 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 73 | 0.070 |
Why?
|
| Aspartate Aminotransferases | 1 | 2009 | 75 | 0.070 |
Why?
|
| Body Weight | 1 | 2010 | 460 | 0.070 |
Why?
|
| Program Development | 1 | 2009 | 136 | 0.070 |
Why?
|
| Patients | 1 | 2010 | 108 | 0.070 |
Why?
|
| Dextroamphetamine | 1 | 2010 | 108 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1773 | 0.070 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 456 | 0.070 |
Why?
|
| Pain Measurement | 1 | 2009 | 378 | 0.070 |
Why?
|
| Arousal | 2 | 2005 | 173 | 0.070 |
Why?
|
| Psychological Tests | 1 | 2008 | 91 | 0.070 |
Why?
|
| Wechsler Scales | 1 | 2007 | 21 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2008 | 105 | 0.070 |
Why?
|
| Administration, Intranasal | 2 | 2018 | 140 | 0.070 |
Why?
|
| Psychopharmacology | 1 | 2006 | 26 | 0.060 |
Why?
|
| Temperance | 2 | 2003 | 6 | 0.060 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2007 | 224 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2004 | 363 | 0.060 |
Why?
|
| Behavior | 1 | 2006 | 87 | 0.060 |
Why?
|
| Models, Psychological | 1 | 2006 | 166 | 0.060 |
Why?
|
| Neoplasms | 1 | 2020 | 3248 | 0.050 |
Why?
|
| Liver | 1 | 2009 | 1238 | 0.050 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2024 | 23 | 0.050 |
Why?
|
| Risk-Taking | 1 | 2025 | 163 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 7230 | 0.050 |
Why?
|
| Anxiety | 2 | 2020 | 339 | 0.050 |
Why?
|
| Forecasting | 1 | 2004 | 317 | 0.050 |
Why?
|
| Personality Assessment | 1 | 2003 | 99 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2004 | 165 | 0.050 |
Why?
|
| Biotransformation | 1 | 2002 | 49 | 0.050 |
Why?
|
| Actigraphy | 1 | 2022 | 61 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 276 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 1010 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2003 | 252 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2024 | 221 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2002 | 244 | 0.040 |
Why?
|
| Alcohol Deterrents | 1 | 2020 | 2 | 0.040 |
Why?
|
| Logistic Models | 1 | 2004 | 1268 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2007 | 806 | 0.040 |
Why?
|
| Colitis, Ulcerative | 1 | 2007 | 801 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2022 | 300 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 484 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 174 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2020 | 229 | 0.040 |
Why?
|
| Oxytocics | 1 | 2018 | 25 | 0.040 |
Why?
|
| Sleep | 1 | 2022 | 458 | 0.040 |
Why?
|
| Universities | 1 | 2019 | 154 | 0.030 |
Why?
|
| Reference Values | 2 | 2012 | 675 | 0.030 |
Why?
|
| Hypertension | 1 | 2003 | 777 | 0.030 |
Why?
|
| Algorithms | 1 | 2025 | 2015 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1179 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2013 | 157 | 0.020 |
Why?
|
| Psychophysics | 1 | 2012 | 80 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 1011 | 0.020 |
Why?
|
| Varenicline | 1 | 2012 | 16 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2015 | 929 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2013 | 333 | 0.020 |
Why?
|
| Nausea | 1 | 2012 | 182 | 0.020 |
Why?
|
| Body Image | 1 | 2010 | 84 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 1323 | 0.020 |
Why?
|
| Income | 1 | 2009 | 90 | 0.020 |
Why?
|
| Individuality | 1 | 2010 | 114 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 1010 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 231 | 0.020 |
Why?
|
| Age of Onset | 1 | 2007 | 344 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2010 | 781 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1807 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 2003 | 54 | 0.010 |
Why?
|
| Isometric Contraction | 1 | 2003 | 41 | 0.010 |
Why?
|
| Hand Strength | 1 | 2003 | 63 | 0.010 |
Why?
|
| Patient Admission | 1 | 2003 | 122 | 0.010 |
Why?
|
| Speech | 1 | 2003 | 91 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 1096 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 599 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2002 | 549 | 0.010 |
Why?
|